Nonalcoholic Steatohepatitis (NASH)

Infectious Disease·MeSH: Non-alcoholic Fatty Liver Disease

Prevalence

5000.0 / 100K

Incidence

500.0 / 100K/yr

10 drugs in development·10 companies·8 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
orbera	Apollo Endosurgery, Inc. (APEN)

Phase 3(1)

Drug	Company
Pegozafermin	89bio, Inc. (ETNB)

Phase 2(4)

Drug	Company
ngm282	NGM BIOPHARMACEUTICALS INC (NGM)
PLN-1474	PLIANT THERAPEUTICS, INC. (PLRX)
Rencofilstat (formerly CRV431; CPI-431-32)	Hepion Pharmaceuticals, Inc. (CTRVP)
seladelpar	CymaBay Therapeutics, Inc. (CBAY)

Phase 1(2)

Drug	Company
aramchol free acid	Galmed Pharmaceuticals Ltd. (GLMD)
miricorilant	CORCEPT THERAPEUTICS INC (CORT)

Preclinical(1)

Drug	Company
jkb-122	Biostax Corp. (BTAX)

Phase 1/Phase 2(1)

Drug	Company
ft-4101	Forma Therapeutics Holdings, Inc. (FMTX)

BioSniper tracks 10 drugs in development for Nonalcoholic Steatohepatitis (NASH) across 10 companies.

There are 8 clinical trials targeting Nonalcoholic Steatohepatitis (NASH) tracked by BioSniper.

The estimated prevalence of Nonalcoholic Steatohepatitis (NASH) is approximately 5000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.